A Phase 3 interventional study of Rufinamide and Any other approved Antiepileptic Drug in Lennox-Gastaut Syndrome, sponsored by Eisai Inc.. Completed at 47 sites in 7 countries. Open to participants aged 1 Year to 3 Years. Per ClinicalTrials.gov, last updated 2019-08-06.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Lennox Gastaut Syndrome with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Lennox Gastaut Syndrome · United States.
Among the 38 studies in Lennox Gastaut Syndrome with a site in United States, this one is the 20th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2011, is one of 16 in phase 3, and was the 5th registered.
68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.
Browse Lennox Gastaut Syndrome studies →7 of the 38 studies in Lennox Gastaut Syndrome with a site in United States are open now. Recruiting first, the newest first:
Epygenix · Sites in United States, China, Hungary and 7 more countries
Ages 2–55
SK Life Science, Inc. · Sites in United States, Argentina, Australia and 13 more countries
Ages 4–55
University of Chicago · Sites in United States
Ages 2–35
Byteflies · Sites in United States
Ages 3+
Longboard Pharmaceuticals · Sites in United States, Australia, Belgium and 14 more countries
Ages 2–66
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Lennox Gastaut Syndrome studies recruiting now, none set no upper age limit and 4 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 1 Year to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 16 · Phase 4 2
First in 1992; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.
Median enrollment 52 across the 32 interventional studies, 394 across the 4 observational. Of the 26 that completed or were terminated, 15 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 8 studies filed under Lennox Gastaut Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Lennox Gastaut Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05219617Phase 3SK Life Science, Inc.Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | 2027-02 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT05339126NeuroPaceRNS System LGS Feasibility Study | 2026-11-30 |
| NCT06738732Alexander RotenbergCBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome | 2027-01 |
| NCT05044819Jazz PharmaceuticalsAssessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Lennox Gastaut Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic drugs.
Key Inclusion:
Key Exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rufinamide
Drug: Any other approved Antiepileptic Drug
Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
Child Behavior Checklist (CBCL) Total Problem T-scores at the End of 2-year Treatment Period
CBCL: 99-item questionnaire measures specific behavioral problems or developmental delays, answered by a parent/legal guardian or suitable caregiver. Each item were rated using 3-point scale (0=Not True, 1=Somewhat/Sometimes True, 2=Very True/ Often True) to indicate how often or typical the behavior was. The 99 items were combined to yield scores for 8 problem area scales (emotionally reactive, anxious/depressed, somatic complaints, withdrawn, sleep problems, attention problems, aggressive behavior, and other problems) and 3 summary scores (internalizing, externalizing, and total problems). Total Problem score was sum of all the problem areas plus 1 additional item, ranging from 0 to 198. Total raw scores are converted to t-scores with mean of 50 and standard deviation (SD) of 10. T-scores were standardized test scores that indicate same degree of elevation in problems relative to the normative sample of peers. Higher scores were indicative of more problems.
Time frame: End of Treatment Period (up to approximately Week 106)
Change From Baseline in CBCL Total Problem T-Scores at End of 2-year Treatment Period
CBCL: 99-item questionnaire measures specific behavioral problems or developmental delays, answered by a parent/legal guardian or suitable caregiver. Each item were rated using 3-point scale (0=Not True, 1=Somewhat/Sometimes True, 2=Very True/ Often True) to indicate how often or typical the behavior was. The 99 items were combined to yield scores for 8 problem area scales (emotionally reactive, anxious/depressed, somatic complaints, withdrawn, sleep problems, attention problems, aggressive behavior, and other problems) and 3 summary scores (internalizing, externalizing, and total problems). Total Problem score was sum of all the problem areas plus 1 additional item, ranging from 0 to 198. Total raw scores are converted to t-scores with mean of 50 and standard deviation (SD) of 10. T-scores were standardized test scores that indicate same degree of elevation in problems relative to the normative sample of peers. Higher scores were indicative of more problems.
Time frame: Baseline and End of Treatment Period (up to approximately Week 106)
Time to Withdrawal From Treatment Due to an Adverse Event or Lack of Efficacy
Withdrawal from either rufinamide or other AED was due to the occurrence of an adverse event or for lack of efficacy. Data was obtained till Week 106 and was extrapolated using Kaplan-Meier method to determine the overall survival time (in weeks) to withdrawal from treatment (excluding taper) due to an adverse event or lack efficacy.
Time frame: Baseline up to the End of the Treatment Period (up to approximately Week 106)
Percent Change in Total Seizure Frequency Per 28 Days
The frequency per 28 days was defined as (S/D)\*28 where, S was equal to the sum of the seizures reported in the participant seizure diary during the specified time interval and D was equal to the number of days with non-missing data in the participant seizure diary for the specified study phase. The number of seizures was assessed and recorded by the participant's parent(s)/caregiver(s) in the participant seizure diary.
Time frame: Baseline up to End of the Treatment Period (up to approximately Week 106)
Percent Change in Seizure Frequency by Individual Seizure Type Per 28 Days
The frequency per 28 days was defined as (S/D)\*28 where, S was equal to the sum of the seizures reported in the participant seizure diary during the specified time interval and D was equal to the number of days with non-missing data in the participant seizure diary for the specified study phase. The number of seizures was assessed and recorded by the participant's parent(s)/caregiver(s) in the participant seizure diary.
Time frame: Baseline up to End of Treatment Period (up to approximately Week 106)
Incidence of Worsening of Seizures
Worsening of seizures was summarized by the incidence of participants with doubling in total seizure frequency, doubling in frequency of major seizures (generalized tonic-clonic, drop attacks), or occurrence of new seizure type during each successive 3 to 4 month visit interval of the Maintenance Period relative to baseline.
Time frame: Baseline up to End of Treatment Period (up to approximately Week 106)
Change From Baseline in CBCL Sub Scores at Week 106
CBCL: 99-item questionnaire, measures behavioral problems/developmental delays, answered by parent/guardian/caregiver. Each item rated on 3-point scale (0=Not True,1=Somewhat/Sometimes True, 2=Very/Often True). 99 items were combined to give scores for 8 problem area scales, where 1 for each 8 syndrome (emotionally reactive, anxious/depressed, somatic, withdrawn, sleep, attention, aggressive behavior, and other problems) were calculated, range: 0 (normal) to 16 (clinical behavior) and 3 summary scores (internalizing, externalizing, and total problems). All 3 summary scores reported scaled to T-scores. Total Problem score was sum of all the problem areas plus 1 additional item, ranging from 0 to 198. Total raw score were converted to t-scores with mean of 50 and SD of 10. T-scores were standardized test scores that indicate same degree of elevation in problems relative to normative sample of peers. Higher scores were indicative of more problems.
Time frame: Baseline and Week 106
Change From Baseline in Language Development Survey (LDS) Scores During Maintenance Period
LDS, a caregiver-administered survey consisted of 8-item questionnaire and vocabulary list of 310 words organized within 14 semantic categories. List contained high frequency words (e.g. more), less common words (e.g. hamburger), and lexical chunks (e.g. Sesame Street). Average LDS score, calculated by dividing total number of words across all valid phrases by number of phrases with greater than (\>) 0words; for participants with no words, average was 0. This value was compared to standardized chart to obtain percentile rating. LDS provided 2 scores: average phrase length (number of words/phrase) and number of endorsed vocabulary words. LDS phrase length was categorized into delay (less than or equal to \[\<=\] 20th percentile) and no delay (\>20th percentile). LDS vocabulary was categorized into delay(\<=15th percentile)and no delay(\>15th percentile). Both raw scores were used to provide 2 normative scores based on child's age in months. Higher scores indicated better language development.
Time frame: Baseline, Weeks 24, 56, 88, and 106
Change From Baseline in Total Score of Quality of Life in Childhood Epilepsy (QoLCE) Scale
The QoLCE was a 76-item questionnaire designed specifically to measure quality of life in children with epilepsy. QOLCE consists of 16 quality of life subscales (14 multi-item and 2 single item). Each subscales had number of items or questions with responses as excellent, very good, good, fair, and poor. They were changed to 1, 2, 3, 4, and 5 as per instructions. Then changed on a scale of 100, where 1 is equal to (=) 0, 2=25, 3=50, 4=75, and 5=100. Items corresponding to each subscale were marked and there mean score was score of that subscale. The form was completed by a parent or caregiver who interacted with the child on a consistent, daily basis and took about 20 to 30 minutes to complete. The higher the score, the better the child's quality of life.
Time frame: Baseline and Week 106
Change From Baseline in Sub-scores in QoLCE
The QoLCE was a 76-item questionnaire designed specifically to measure quality of life in children with epilepsy. QOLCE consists of 16 quality of life subscales (14 multi-item and 2 single item). Each subscales had number of items or questions with responses as excellent, very good, good, fair, and poor. They were changed to 1, 2, 3, 4, and 5 as per instructions. Then changed on a scale of 100, where 1=0, 2=25, 3=50, 4=75, and 5=100. Items corresponding to each subscale were marked and there mean score was score of that subscale. The form was completed by a parent or caregiver who interacted with the child on a consistent, daily basis and took about 20 to 30 minutes to complete. The higher the score, the better the child's quality of life.
Time frame: Baseline and Week 106
Participants took part in the study at 19 investigative sites in the United States, Canada, France, Greece, Italy, and Poland from 16 June 2011 to 02 November 2015.
| Milestone | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Started | 25 | 12 |
| Completed | 15 | 4 |
| Not completed | 10 | 8 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Participant choice | 2 | 1 |
| Withdrew: Inadequate therapeutic effect | 2 | 1 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Other | 0 | 1 |
CBCL: 99-item questionnaire measures specific behavioral problems or developmental delays, answered by a parent/legal guardian or suitable caregiver. Each item were rated using 3-point scale (0=Not True, 1=Somewhat/Sometimes True, 2=Very True/ Often True) to indicate how often or typical the behavior was. The 99 items were combined to yield scores for 8 problem area scales (emotionally reactive, anxious/depressed, somatic complaints, withdrawn, sleep problems, attention problems, aggressive behavior, and other problems) and 3 summary scores (internalizing, externalizing, and total problems). Total Problem score was sum of all the problem areas plus 1 additional item, ranging from 0 to 198. Total raw scores are converted to t-scores with mean of 50 and standard deviation (SD) of 10. T-scores were standardized test scores that indicate same degree of elevation in problems relative to the normative sample of peers. Higher scores were indicative of more problems.
| score on a scale | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Child Behavior Checklist (CBCL) Total Problem T-scores at the End of 2-year Treatment Period | 55.7 ± 15.81 | 54.8 ± 4.50 |
CBCL: 99-item questionnaire measures specific behavioral problems or developmental delays, answered by a parent/legal guardian or suitable caregiver. Each item were rated using 3-point scale (0=Not True, 1=Somewhat/Sometimes True, 2=Very True/ Often True) to indicate how often or typical the behavior was. The 99 items were combined to yield scores for 8 problem area scales (emotionally reactive, anxious/depressed, somatic complaints, withdrawn, sleep problems, attention problems, aggressive behavior, and other problems) and 3 summary scores (internalizing, externalizing, and total problems). Total Problem score was sum of all the problem areas plus 1 additional item, ranging from 0 to 198. Total raw scores are converted to t-scores with mean of 50 and standard deviation (SD) of 10. T-scores were standardized test scores that indicate same degree of elevation in problems relative to the normative sample of peers. Higher scores were indicative of more problems.
| score on a scale | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Baseline | 56.6 ± 11.27 | 62.8 ± 13.07 |
| Change at Week 106 | -0.3 ± 15.72 | -6.7 ± 0.58 |
Withdrawal from either rufinamide or other AED was due to the occurrence of an adverse event or for lack of efficacy. Data was obtained till Week 106 and was extrapolated using Kaplan-Meier method to determine the overall survival time (in weeks) to withdrawal from treatment (excluding taper) due to an adverse event or lack efficacy.
| weeks | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Time to Withdrawal From Treatment Due to an Adverse Event or Lack of Efficacy | 142.0 (NA to NA) | 28.0 (17.7 to NA) |
The frequency per 28 days was defined as (S/D)\*28 where, S was equal to the sum of the seizures reported in the participant seizure diary during the specified time interval and D was equal to the number of days with non-missing data in the participant seizure diary for the specified study phase. The number of seizures was assessed and recorded by the participant's parent(s)/caregiver(s) in the participant seizure diary.
| percent change in seizure frequency | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Percent Change in Total Seizure Frequency Per 28 Days | -7.05 (-79.2 to 3644.1) | -20.15 (-83.3 to 143.1) |
The frequency per 28 days was defined as (S/D)\*28 where, S was equal to the sum of the seizures reported in the participant seizure diary during the specified time interval and D was equal to the number of days with non-missing data in the participant seizure diary for the specified study phase. The number of seizures was assessed and recorded by the participant's parent(s)/caregiver(s) in the participant seizure diary.
| percent change in seizure frequency | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Partial seizures | -39.8 (-100.0 to 52281.9) | -57.65 (-98.1 to -17.2) |
| Absence seizures | -23.6 (-100.0 to 86.8) | -49.70 (-98.9 to 1846.7) |
| Atypical absence seizures | -70.95 (-100.0 to 16825.4) | 4.90 (-90.9 to 1189.7) |
| Myoclonic seizures | -24.60 (-73.3 to 11462.4) | -27.90 (-60.9 to 130.2) |
| Clonic seizures | -60.85 (-100.0 to 140.4) | -48.35 (-54.2 to -42.5) |
| Tonic-atonic seizures | -35.20 (-100.0 to 1250.6) | -31.80 (-81.9 to -4.0) |
| Primary generalized tonic-clonic seizures | -97.80 (-100.0 to 37.6) | -96.60 (-96.6 to -96.6) |
| Other seizures | -90.65 (-100.0 to 183.8) | -100.00 (-100.0 to -54.0) |
Worsening of seizures was summarized by the incidence of participants with doubling in total seizure frequency, doubling in frequency of major seizures (generalized tonic-clonic, drop attacks), or occurrence of new seizure type during each successive 3 to 4 month visit interval of the Maintenance Period relative to baseline.
| Participants | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Doubling in total seizure frequency | 4 | 1 |
| Doubling in frequency of major seizures | 5 | 1 |
| Occurrence of a new seizure type | 0 | 0 |
CBCL: 99-item questionnaire, measures behavioral problems/developmental delays, answered by parent/guardian/caregiver. Each item rated on 3-point scale (0=Not True,1=Somewhat/Sometimes True, 2=Very/Often True). 99 items were combined to give scores for 8 problem area scales, where 1 for each 8 syndrome (emotionally reactive, anxious/depressed, somatic, withdrawn, sleep, attention, aggressive behavior, and other problems) were calculated, range: 0 (normal) to 16 (clinical behavior) and 3 summary scores (internalizing, externalizing, and total problems). All 3 summary scores reported scaled to T-scores. Total Problem score was sum of all the problem areas plus 1 additional item, ranging from 0 to 198. Total raw score were converted to t-scores with mean of 50 and SD of 10. T-scores were standardized test scores that indicate same degree of elevation in problems relative to normative sample of peers. Higher scores were indicative of more problems.
| score on a scale | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Baseline: Total emotional reactive scores | 59.0 ± 8.13 | 60.9 ± 8.64 |
| Change at Week 106:Total emotional reactive scores | -1.1 ± 9.30 | -1.3 ± 6.11 |
| Baseline: Total anxious/depression scores | 56.4 ± 7.48 | 54.6 ± 6.67 |
| Change at Week 106:Total anxious/depression scores | 0.5 ± 8.87 | 0.7 ± 1.15 |
| Baseline: Total Somatic Complaints Scores | 59.4 ± 8.13 | 54.9 ± 4.70 |
| Change at Week 106:Total Somatic Complaints Scores | 0.1 ± 11.24 | -1.7 ± 2.89 |
| Baseline: Total withdrawn scores | 71.5 ± 11.72 | 72.1 ± 11.03 |
| Change at Week 106:Total withdrawn scores | -2.2 ± 13.22 | -7.0 ± 9.54 |
| Baseline: Total Sleep Problems Scores | 57.8 ± 10.72 | 62.4 ± 8.57 |
| Change at Week 106:Total sleep problem scores | -1.9 ± 12.30 | -5.7 ± 7.57 |
| Baseline: Total attention problems scores | 59.3 ± 9.17 | 65.9 ± 10.72 |
| Change at Week 106:Total attention problems scores | -1.1 ± 4.65 | -7.7 ± 2.52 |
| Baseline: Total Aggressive Behavior Scores | 52.5 ± 5.01 | 58.6 ± 12.07 |
| Change at Week106:Total aggressive behavior scores | 3.2 ± 6.26 | -0.3 ± 2.89 |
| Baseline: Total internalizing scores | 61.6 ± 10.78 | 60.6 ± 9.71 |
| Change at Week 106:Total internalizing scores | -1.5 ± 13.73 | -2.7 ± 1.53 |
| Baseline: Total externalizing scores | 47.5 ± 11.22 | 58.1 ± 15.92 |
| Change at Week 106:Total externalizing scores | 4.7 ± 10.07 | -3.7 ± 3.51 |
LDS, a caregiver-administered survey consisted of 8-item questionnaire and vocabulary list of 310 words organized within 14 semantic categories. List contained high frequency words (e.g. more), less common words (e.g. hamburger), and lexical chunks (e.g. Sesame Street). Average LDS score, calculated by dividing total number of words across all valid phrases by number of phrases with greater than (\>) 0words; for participants with no words, average was 0. This value was compared to standardized chart to obtain percentile rating. LDS provided 2 scores: average phrase length (number of words/phrase) and number of endorsed vocabulary words. LDS phrase length was categorized into delay (less than or equal to \[\<=\] 20th percentile) and no delay (\>20th percentile). LDS vocabulary was categorized into delay(\<=15th percentile)and no delay(\>15th percentile). Both raw scores were used to provide 2 normative scores based on child's age in months. Higher scores indicated better language development.
| words | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Baseline: LDS average phrase length | 0.3 ± 0.87 | 0 ± 0.00 |
| Change at Week 24: LDS average phrase length | 0.2 ± 1.11 | 0.7 ± 1.28 |
| Change at Week 56: LDS average phrase length | 0.1 ± 1.02 | 0.0 ± 0.00 |
| Change at Week 88: LDS average phrase length | 0.1 ± 1.03 | 0.0 ± 0.00 |
| Change at Week 106: LDS average phrase length | 0.4 ± 1.12 | 0.0 ± 0.00 |
| Baseline:LDS Vocabulary Score | 10.4 ± 37.72 | 0.6 ± 1.67 |
| Change at Week 24:LDS Vocabulary Score | 7.1 ± 21.55 | 4.8 ± 8.22 |
| Change at Week 56:LDS Vocabulary Score | 17.9 ± 39.24 | -0.40 ± 2.15 |
| Change at Week 88:LDS Vocabulary Score | 25.4 ± 49.87 | 0.0 ± 0.00 |
| Change at Week 106:LDS Vocabulary Score | 39.6 ± 75.62 | 1.0 ± 2.00 |
The QoLCE was a 76-item questionnaire designed specifically to measure quality of life in children with epilepsy. QOLCE consists of 16 quality of life subscales (14 multi-item and 2 single item). Each subscales had number of items or questions with responses as excellent, very good, good, fair, and poor. They were changed to 1, 2, 3, 4, and 5 as per instructions. Then changed on a scale of 100, where 1 is equal to (=) 0, 2=25, 3=50, 4=75, and 5=100. Items corresponding to each subscale were marked and there mean score was score of that subscale. The form was completed by a parent or caregiver who interacted with the child on a consistent, daily basis and took about 20 to 30 minutes to complete. The higher the score, the better the child's quality of life.
| score on a scale | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Baseline | 50.4 ± 10.05 | 49.6 ± 7.88 |
| Week 106 | -1.3 ± 8.49 | 1.5 ± 1.00 |
The QoLCE was a 76-item questionnaire designed specifically to measure quality of life in children with epilepsy. QOLCE consists of 16 quality of life subscales (14 multi-item and 2 single item). Each subscales had number of items or questions with responses as excellent, very good, good, fair, and poor. They were changed to 1, 2, 3, 4, and 5 as per instructions. Then changed on a scale of 100, where 1=0, 2=25, 3=50, 4=75, and 5=100. Items corresponding to each subscale were marked and there mean score was score of that subscale. The form was completed by a parent or caregiver who interacted with the child on a consistent, daily basis and took about 20 to 30 minutes to complete. The higher the score, the better the child's quality of life.
| score on a scale | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Baseline: Physical restriction | 50.1 ± 10.33 | 49.9 ± 8.23 |
| Change at Week 106: Physical restriction | -1.0 ± 7.51 | -6.8 ± 7.32 |
| Baseline: Energy/Fatigue | 51.6 ± 10.48 | 44.3 ± 4.55 |
| Change at Week 106: Energy/Fatigue | -3.1 ± 12.22 | 2.8 ± 4.11 |
| Baseline: Attention/Concentration | 49.9 ± 10.14 | 51.1 ± 9.05 |
| Change at Week 106:Attention/Concentration | -2.1 ± 7.31 | 2.5 ± 6.24 |
| Baseline: Memory | 50.2 ± 9.54 | 52.6 ± 6.57 |
| Change at Week 106: Memory | -0.5 ± 12.18 | 0.5 ± 1.00 |
| Baseline: Language | 49.8 ± 10.42 | 53.1 ± 4.43 |
| Change at Week 106: Language | -0.5 ± 9.63 | -0.5 ± 11.56 |
| Baseline: Other cognitive | 48.6 ± 10.32 | 53.1 ± 7.54 |
| Change at Week 106: Other cognitive | 0.3 ± 6.19 | -1.0 ± 4.00 |
| Baseline: Depression | 51.2 ± 9.27 | 45.3 ± 10.59 |
| Change at Week 106: Depression | -2.6 ± 11.64 | 2.3 ± 8.62 |
| Baseline: Anxiety | 50.1 ± 10.27 | 48.5 ± 12.29 |
| Change at Week 106: Anxiety | -0.1 ± 12.12 | 1.3 ± 6.90 |
| Baseline: Control/Helplessness | 50.7 ± 9.31 | 47.8 ± 12.27 |
| Change at Week 106: Control/Helplessness | 0.2 ± 10.90 | 3.0 ± 11.52 |
| Baseline: Self-esteem | 50.1 ± 10.18 | 50.5 ± 10.98 |
| Change at Week 106: Self-esteem | -1.3 ± 9.48 | -6.0 ± 8.08 |
| Baseline: Social interactions | 49.9 ± 10.56 | 50.5 ± 8.48 |
| Change at Week 106: Social interactions | -1.5 ± 11.64 | 4.0 ± 5.89 |
| Baseline: Social activities | 50.5 ± 10.50 | 46.6 ± 3.96 |
| Change at Week 106: Social activities | 0.9 ± 11.30 | 3.5 ± 3.70 |
| Baseline: Stigma | 48.9 ± 11.06 | 50.7 ± 8.07 |
| Change at Week 106: Stigma | -0.1 ± 12.67 | 4.5 ± 10.25 |
| Baseline: Behavior | 51.4 ± 10.39 | 45.8 ± 9.33 |
| Change at Week 106: Behavior | 0.2 ± 5.92 | 7.3 ± 6.55 |
| Baseline: General-health | 50.5 ± 10.02 | 49.0 ± 8.40 |
| Change at Week 106: General health | -1.3 ± 10.98 | -2.0 ± 10.86 |
| Baseline: Quality-of-life | 49.5 ± 9.71 | 50.7 ± 9.98 |
| Change at Week 106: Quality-of-life | 1.1 ± 9.46 | 3.3 ± 12.28 |
Collected over From Visit 1 up to 30 days after the last study visit, or until resolution, whichever came first (up to approximately Week 106). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rufinamide | 1/25 (4%) | 10/25 (40%) | 21/25 (84%) |
| Any Other Approved Antiepileptic Drug | 0/12 (0%) | 5/12 (41.7%) | 10/12 (83.3%) |
| Event | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| SeizureNervous system disorders | 1/25 | 3/12 |
| BronchopneumoniaInfections and infestations | 1/25 | 1/12 |
| Joint dislocationInjury, poisoning and procedural complications | 0/25 | 1/12 |
| DehydrationMetabolism and nutrition disorders | 0/25 | 1/12 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/25 | 1/12 |
| LethargyNervous system disorders | 0/25 | 1/12 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 2/25 | 1/12 |
| Status epilepticusNervous system disorders | 2/25 | 0/12 |
| BlindnessEye disorders | 1/25 | 0/12 |
| BronchitisInfections and infestations | 1/25 | 0/12 |
| Event | Rufinamide | Any Other Approved Antiepileptic Drug |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/25 | 4/12 |
| VomitingGastrointestinal disorders | 7/25 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 4/25 | 3/12 |
| PyrexiaGeneral disorders | 4/25 | 3/12 |
| SomnolenceNervous system disorders | 5/25 | 0/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/25 | 2/12 |
| Otitis mediaInfections and infestations | 4/25 | 0/12 |
| PneumoniaInfections and infestations | 4/25 | 0/12 |
| SinusitisInfections and infestations | 4/25 | 1/12 |
| ConstipationGastrointestinal disorders | 3/25 | 1/12 |
The safety analysis set included all enrolled participants who received at least 1 dose of rufinamide or any other approved add-on AED of the investigator's choice and had at least 1 postdose safety assessment.
| Age, Continuous(months) | Rufinamide | Any Other Approved Antiepileptic Drug | Total |
|---|---|---|---|
| Mean | 28.3 ± 9.99 | 29.8 ± 9.85 | 28.8 ± 9.83 |
| Sex: Female, Male(Participants) | Rufinamide | Any Other Approved Antiepileptic Drug | Total |
|---|---|---|---|
| Female | 11 | 2 | 13 |
| Male | 14 | 10 | 24 |
Ran from Jun 2011 to primary completion in Nov 2015, 52 months.
Results were first posted in Aug 2019, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rufinamide